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Resumo 
O cancro é ainda uma das principais causas de morte e é facto que um diagnóstico 
precoce aumenta significativamente as possibilidades de sobrevivência do paciente, 
otimizando a eficácia do tratamento. Este objectivo pode ser atingido através de um 
equipamento adequado de detecção e um agente de contraste. 
A Ressonância Magnética (RM) é uma técnica clinica de imagem com alta resolução 
espacial e contraste dos tecidos moles que permite uma visualização não-invasiva e 
tomográfica de estruturas anatómicas. É hoje aceite que agentes de contraste magnéticos de 
dimensão nanométrica são capazes de maximizar a sensibilidade da RM encurtando os tempos 
de relaxividade dos protões da água presentes nas áreas dos tecidos onde o agente se 
acumula. Estes agentes caracterizam-se por apresentarem vantagens distintas em relação aos 
agentes de contraste convencionais, nomeadamente pela sua elevada área de superfície, pela 
possibilidade de entrega específica a uma localização tumoral-alvo e pela possibilidade de 
projetar o seu tempo de circulação sanguíneo ou outras características relevantes. 
A citotoxicidade é ainda uma questão importante que limita a aplicação clínica de muitos 
nano-agentes de contraste propostos até agora. A hidroxiapatite é um composto biocerâmico 
que não só incorpora iões facilmente, mas também confere biocompatibilidade ao sistema, o 
que faz a sua conjugação com iões magnéticos uma abordagem apelativa na imagem 
localizada de cancro. Tentativas consideráveis têm sido realizadas no âmbito deste tema, mas 
existe ainda uma necessidade para estandardizar procedimentos e comparar sistemas nano 
capazes de realçar o contraste tumoral e potencialmente poderiam permitir uma detecção 
específica de cancro. 
No presente trabalho, nanoparticulas de hidroxiapatite dopadas com iões magnéticos 
foram produzidas com êxito por um método otimizado e reproduzível de precipitação 
química. Apurou-se que todas as partículas de nanohidroxiapatite dopadas de Gd, Fe(II), 
Fe(III) e Co possuíam a forma de bastonete e um tamanho médio entre 30 e 60nm.  
A estrutura principal de hidroxiapatite não foi alterada pela percentagem de dopagem 
embora esta se tenha provado como diretamente proporcional aos níveis de momento 
magnético da amostra. Hidroxiapatite dopada com 10% Gd apresentou os níveis mais altos de 
  
vi 
momento magnético entre todos os iões dopantes e também os valores mais próximos dos de 
um agente de contraste já comercializado.  
A viabilidade e a morfologia de células humanas microvasculares endoteliais da derme não 
sugerem uma alteração significativa após incubação com os materiais sintetizados. 
Com efeito, os resultados mostram que as nanoparticulas de hidroxiapatite dopadas com 
10% Gd são as mais promissoras dentro do grupo testado e, portanto, podem tornar-se um 
valioso biomaterial para agente de contraste de RM.             
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Abstract 
Cancer is still one of the main causes of death and it is known that an early diagnostic 
significantly increases chances of survival of the patient, optimizing the efficacy of the 
treatment. This can be achieved with an appropriate detection device and contrast agent. 
Magnetic Resonance Imaging (MRI) is a clinical imaging technique that allows for 
noninvasive tomographic visualization of anatomic structures with high spatial resolution and 
soft tissue contrast. It is well accepted that nanosized magnetic contrast agents can maximize 
MRI sensitivity shortening the relaxation times of bulk water protons in tissue where the agent 
accumulates. They are characterized by distinct advantages over conventional contrast 
agents namely their high surface area, possibility of delivery to a specific cancer site by 
active targeting and the possibility of engineering their blood circulation half-life, among 
others.  
Cytotoxicity is still a major issue that limits the clinical application of many nano-contrast 
agents proposed so far. Bioceramic hydroxyapatite not only easily incorporates ions but also 
confers biocompatibility to the system which makes its conjugation with magnetically 
responsive ions an appealing approach in targeted cancer imaging. Considerable attempts 
have been made within this subject but there is a need to standardize procedures and 
compare nanosized systems capable of enhancing tumor contrast that would hereafter allow 
targeted cancer detection.        
In the present work, magnetic ion doped hydroxyapatite nanoparticles were successfully 
produced by an optimized and reproducible wet chemical precipitation method. It was found 
that all Gd, Fe(II), Fe(III) and Co doped nanohydroxyapatite particles were rod-like shaped 
and of average size between 30 and 60nm.  
 Main hydroxyapatite structure was not altered by the percentage of doping although this 
percentage was proven to be directly proportional to the magnetic moment levels of the 
sample. 10% Gd doped HAP presented the highest magnetic moment levels between all doping 
ions and also the closest values to the ones of a commercialized contrast agent. 
Viability and morphology of human dermal microvascular endothelial cells did not seem to 
be significantly altered after incubation with the synthesized materials.  
  
viii 
In effect, the results show that 10% Gd doped nanohydroxyapatite is the most promising 
from the group of nanoparticles tested and therefore can be a valuable biomaterial contrast 
agent for MR imaging. 
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Expect problems and  
eat them for breakfast. 
 
Alfred A. Montapert 
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  Chapter 1
Introduction 
1.1 - Cancer Disease 
1.1.1 - Physiological characteristics of benign and malignant solid 
tumors 
Not only cancer is a major public health problem, with estimated 5.2 million new cases of 
cancer diagnosed in OECD countries[1] and an average of 83 million years of “healthy life” 
lost due to death and disability in 2008, but this also constituted a total economic impact of 
$895 billion worldwide in the same year[2]. So, even though research efforts to improve 
current cancer therapies over the past three decades have led to an improvement in patient 
survival, there is still a need for new and better strategies. 
But, in order to develop new therapies for cancer treatment, it is crucial to get a better 
insight of tumors. 
In common medical usage, a neoplasm, a mass of tissue that continuously replicates which 
is not influenced by the regulatory processes that control normal cell growth, is often 
referred to as a tumor.  
In general, all tumors have two basic components: the parenchyma, which is constituted 
by transformed or neoplastic cells and determines the neoplasm behavior, and the non-
neoplastic stroma, which, in turn, consists of connective tissue, blood vessels and host-
derived inflammatory cells, therefore providing support for the growth of parenchymal cells.  
However, neoplasms or tumors can be categorized into benign or malign, regarding their 
potential clinical behavior and performance according to some parameters: differentiation 
and anaplasia (lack of differentiation), rate of growth, local invasion, and metastasis. 
A benign tumor will remain localized, with no chance of spreading to other sites, can be 
surgically removed and it is considered to be relatively innocent. Nevertheless, benign tumors 
can evolve to a malignant state requiring regular follow-up. 
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Malignant tumors are referred to as cancers and most of them have the ability to invade 
and destroy adjacent structures and spread to distant sites (metastasize) to possibly cause 
death. 
In a more detailed perspective, as illustrated in Table 1, malignant tumors have distinct 
parenchymal cells, from well differentiated to completely undifferentiated states.  It is well 
known that the more differentiated a cell is, the more likely it performs its normal functional 
activities. That said, anaplasia is a common feature in malignant tumors and it involves 
dedifferentiation, loss of the structural and functional differentiation of specialized cells or 
failure of differentiation in stem cells.  Anaplastic nuclei are variable and peculiar in size and 
shape and mitoses are often numerous and distinctly atypical. Therefore, generally, the more 
rapidly growing and the more anaplastic a tumor, the less likely it is to have specialized 
functional activity. 
Malignant tumors also do not present an often feature in the benign ones: an enclosing 
fibrous capsule probably derived from the host stroma that isolates them from the hosting 
environment. Thus, most cancers grow progressively penetrating and destroying surrounding 
tissues without developing well-defined capsules. Metastasizing and local invasion constitute 
the most reliable features that distinguish malignant from benign tumors.    
However, not all cancers have the same ability to metastasize. Examples like basal cell 
carcinomas or primary brain tumors are highly invasive in their primary sites of origin but 
rarely metastasize[3, 4].  
 
Table 1.1 Summary of distinct features of benign and malignant tumors (adapted from 
[5]) 
Because of their rapidly growing feature, most cancers tend to spread locally and to 
distant organism sites, process called metastasizing. Angiogenesis, known as the formation of 
new blood vessels from existing ones, is essential to the transformation of a small, often 
dormant cluster of cancer cells to a solid tumor and also to the metastasizing process, 
hypothesis stated for the first time in 1971 by Judah Folkman[6]. For solid tumors of 1-2mm3, 
simple diffusion is the way oxygen and nutrients reach the center of the tumor, but for solid 
tumors bigger than 2mm3, a state of cellular hypoxia begins, which initiates signaling events 
that upregulate the production of pro-angiogenic factors, such as vascular endothelial growth 
 
BENIGN TUMOR MALIGNANT TUMOR 
Differentiation 
and anaplasia 
Composed of well-differentiated 
cells that closely resemble their 
normal counterparts; mitoses are 
limited in number and of normal 
configuration. 
Characterized by a wide range of 
parenchymal cell differentiation; 
anaplasia is common; mitoses are 
often numerous and distinctly 
atypical. 
Rate of growth Most benign tumors increase in 
size slowly over the span of 
months to years. 
Most cancers progressively enlarge 
over time, some slowly, others 
rapidly. 
Local invasion Remains localized at its site of 
origin. 
Most cancers infiltrate, invade, or 
metastasize to distant sites. 
Metastasis Nonmetastatic Most cancers develop secondary 
implants (metastases) 
discontinuous with the primary 
tumor, in remote tissues. 
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factor. In turn, VEGF regulates endothelial cell proliferation and enhances permeability of the 
microvessels, giving rise to neovasculatures different from those of normal tissues with an 
irregular shape, of high density and heterogeneity and poorly oxygenated, resulting in regions 
of hypoxia.  The lack of oxygen stimulates the tumor cells to have an anaerobic metabolism 
that causes an extracellular acidosis in response to excessive production of lactic acid and 
CO2. It has been reported that extracellular normal tissue pH is around 7.4, whereas 
extracellular tumor pH is generally between 6.0 and 7.0 and this characteristic has been a 
source of interest especially in targeted cancer therapies investigation[7].  The initiation of 
the tumor angiogenesis is crucial to the exponential tumor growth and is called angiogenic 
switch. It can occur at different stages in the tumor-progression pathway and it is defined by 
several distinct phases such as vessel dilation, angiogenic sprouting, new vessel formation and 
maturation and recruitment of perivascular cells.  
In addition, cancer cells tend to compress lymphatic vessels forcing them to collapse, 
therefore creating lack of functional lymphatic system mostly within the tumor central area. 
This characteristic along with a leaky tumor vasculature induces an accumulation of vascular 
contents inside the tumor and an interstitial hypertension which hampers the transport of 
macromolecules from the capillaries to the interstitial fluid[8].  
Also, the tumor microenvironment plays a major role in the modulation of the metastatic 
behavior of most cancers. It is now recognized that primary and metastatic tumors induce the 
mobilization of bone marrow-derived cells that help the tumor to progress, survive and grow 
at a secondary site. As portrayed in Figure 1.1, a plethora of cell types interact with each 
 
Figure 1.1 The primary tumor microenvironment (adapted from [9]) 
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other, responsible for the secretion of, for example, VEGF and matrix metalloproteinases, 
enabling angiogenesis malignant progression. Endothelial cells in the blood and lymphatic 
vessels, pericytes, fibroblasts, macrophages, neutrophils, mast cells, myeloid cell-derived 
suppressor cells, mesenchymal stem cells and TIE2-expressing monocytes are among the main 
cell types that interact with cancer cells[9].  
 
1.1.2 - Current tumor imaging perspective 
Early detection of cancer disease allows the maximum likelihood of successful treatment 
and recovery, since early localization of malignant solid tumors may allow a directed therapy 
to its site, optimizing the efficacy of the treatment. This can be achieved with an appropriate 
detection device.  
The type of information required or the characteristics of the biological target condition 
the performance of the in-vivo imaging technique used and the choice of the contrast agent 
or probe. For instance, MRI is better suited for clinical use than fluorescence imaging, since it 
is more powerful and safer on humans[10].  
Imaging modalities play an important role in the clinical management of cancer, including 
screening, diagnosis, treatment planning and therapy monitoring. Table 2 summarizes the 
most commonly used bioimaging modalities in tumor diagnosis, paying special attention to 
current NP-based contrast agents for each technique (MRI, computed tomography, positron 
emission tomography, single-photon emission computed tomography, ultrasound imaging, 
photoacoustic imaging and near-infrared fluorescence). 
These most commonly used imaging modalities in clinical detection of cancer are all 
nonspecific, therefore they cannot distinguish between malignant or benign tumors and none 
leads to 100% accurate detection. Besides, most of the presented technologies and their 
contrast agents involve exposure to radiation or heavy metals, which present potential health 
risks to patients and limit the ways they can be applied. 
The goal of cancer imaging should be to detect and/or image the smallest possible 
number of tumor cells, since there are currently no reliable methods for in vivo imaging of 
tumors smaller than 1cm3, constituted with approximately 109 cells[11].  
Also, there are certain types of cancer that are still currently hard to detect and image 
such as ovarian cancer because of its extra thin earliest proliferative lesion or pediatric 
cancer, since it is difficult to preform clinical trials in young ages and because they constitute 
a small market size[11]. 
 
1.1.2.1 - Magnetic resonance imaging 
MRI is a non-invasive FDA approved for clinical use imaging technique (since 1985) that 
does not expose the patient to ionizing radiation and offers a high spatial resolution of 
approximately 50μm. It is also accepted that magnetic fields are not contraindicated for 
humans and MR scanners are safe with a static magnetic field of 8 Tesla, except for patients 
whose body contains magnetizable material such as implanted metallic medical devices, 
pacemakers, artificial limbs or tattoos[12, 13].  
MRI is based on the detection of nuclear magnetic resonance signals that are emitted by 
hydrogen protons in body tissues, membrane lipids, proteins, etc., under the effect of a 
magnetic field and it is used for the diagnosis and monitoring of human diseases, since it 
enables whole-organisms anatomical imaging. MRI can quickly produce pictures of wide range 
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of bodily tissues, though the clarity of these pictures is sometimes insufficient for diagnoses, 
which can be improved through the appliance of a contrast agent that enhances the visibility 
of the tissues it is in contact with. 
Technically, the application of a transverse, or perpendicular to the main magnetic field, 
radiofrequency-field induces the transversal magnetization of the hydrogen protons. When 
these try to realign again with the longitudinal axis of the magnetic field, returning to a state 
of equilibrium (relaxation process), an electric field is created, generating the resonance 
signal (Mxy). 
In addition, three tissue parameters influence MRI image contrast, which are sensitivity to 
proton density, longitudinal relaxation times T1 (return of longitudinal magnetization to align 
with the external magnetic field) and transverse relaxation times T2 (vanishing of transverse 
magnetization), which are illustrated in Figure 1.2 (Adapted from [14]). However, here 
remains a possibility of poor contrast between healthy and diseased tissue due to small 
variation in their relaxation times. 
A method to improve image contrast and diagnostic value of MRI is to introduce contrast 
enhancer agents that increase relaxation rates of water protons in tissue where the agent 
accumulates. By manipulating TR and time delay after excitation before the signal is 
measured, the relative contributions of T1 and T2 can be manipulated to produce T1- and T2-
weighted images. More specifically, the agents that increase T1 signal produce a bright 
contrast and those that reduce the T2 signal create a dark contrast. Therefore, agents that 
reduce T1 or T2 relaxation times are said to have individual relaxivities values  [15], [16], [10]. 
1.2 - Nanoparticles in tumor detection 
1.2.1 - Biodistribution of the nanoparticles 
Nanoparticles constitute a very powerful tool in cancer therapy and diagnosis due to some 
key characteristics. Primarily, their size range, 10-100nm, allows NPs use in several 
Figure 1.2 Illustration of longitudinal relaxation time T1 and transverse relaxation time T2. RF 
excitations are applied with a TR (top) with each excitation producing a magnetic resonance signal 
(Mxy) that exponentially decays with a time constant T2 (bottom right). Between excitations, the 
magnetization also exponentially returns to its equilibrium state, pointing along the direction of the 
main magnetic field, with a time constant T1 (bottom left).  
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modifications at the molecular level such as cell-receptor binding for site-selective imaging 
and targeting[17] or for localization of encapsulated therapeutics for delivery[18].  
Notwithstanding, tumor tissues targeting occurs after injection of the NPs into the 
systemic blood circulation, process which depends on the blood capillaries characteristics, 
administration site and surface properties of the NPs. Their biodistribution in the circulation 
blood stream is often associated with a RES uptake, which makes the strategies to stealth for 
long circulation times with minimal nonspecific binding an important area of focus.  
In tumor and inflammatory tissues, or in RES-rich organs (liver, spleen, bone marrow), 
100nm particles can easily penetrate since these tissues present discontinuous basal lamina 
caused by degradation during the abnormal angiogenesis process of tumor growth[8], 
therefore creating discontinuous capillary walls that also have a large number of 
approximately 100nm pores.[19]   
Also, due to specific characteristics of their irrigating system, namely 
hypervascularization, extensive production of vascular permeability factors, lack of smooth 
muscle layer, no constant blood flow and direction and inefficient lymphatic drainage, solid 
tumors exhibit an EPR, which can be an important feature in the design of selective cancer 
diagnosis and therapies techniques. Briefly, once the nano-sized particles coupled with 
macromolecular anticancer/cancer detection drugs are intravenously administered, they 
cannot infiltrate the tight endothelial junctions of normal blood vessels, so they penetrate 
the tumor tissues and become trapped in the interstitium of tumor with no access to the 
lymphatic system and slow venus return[20].  
With an increasing number of nanoparticle formulations under review by the FDA, growing 
government funding, and exponentially increasing submission of patents for novel 
formulations, the outlook for nanoparticle systems in cancer imaging and therapeutics is 
promising.  
 
1.2.2 -  Magnetically responsive nanoparticles 
Magnetic nanoparticles are successful in biomedical applications, particularly as contrast 
agents for MRI, largely because of their enhanced proton relaxation capabilities. It was 
actually in 1978 that Oghushi was one of the firsts to demonstrate that magnetic 
nanoparticles, specifically dextran-magnetite, can reduce the T2 relaxation times in a 
controlled and useful way[21].  
Most commonly used magnetic materials to produce contrast are paramagnetic or 
superparamagnetic substances, mainly superparamagnetic iron oxide particles and soluble 
paramagnetic metal chelates, and this characteristic means that they present net positive 
magnetic susceptibilities, becoming magnetized by an external magnetic field. Iron oxide 
particles consist of specific iron oxide cores and coating materials including dextran. 
Regarding their main application and biodistribution, contrast agents can also be categorized 
into extracellular agents that distribute non-specifically throughout the body and are rapidly 
excreted by the kidneys (portrayed by contrast agents like Magnevist® and Dotarem®, in 
Table 3), into blood pool agents that are larger than extracellular ones so they cannot leak 
into the interstitium and finally into tissue/organ-specific contrast agents which have a 
special affinity for a specific type of cell or receptor and tend to accumulate in the target 
sites.  
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Concerning superparamagnetic contrast agents, first generation magnetic nanoparticles 
were polydisperse SPIO, heterogeneous in size, which were quickly cleared from the blood of 
the liver RES, serving as contrast enhancing agents to detect primary and metastatic hepatic 
tumors[22]. As described in Table 3, MRI approved contrast agents that are currently on the 
market and are specific for liver, such as Feridex IV® or Teslascan®, work in the same way. 
Later, smaller monodisperse iron oxide nanoparticles started to be produced since it was 
shown that smaller particle sizes increased blood circulation time and consequently induced a 
high uptake by the macrophages of the lymph nodes[23].  
 However, iron oxide particles without a surface coating are not stable in aqueous media, 
therefore tending to aggregate and precipitate, being sequestered by macrophages of the RES 
in response to the nonspecific adsorption of plasma proteins to the aggregates. 
Simultaneously, intrinsic superparamagnetic properties are weakened[24]. Concerning the 
structure of this kind of contrast agents, they usually consist of an iron oxide core (Fe3O4) 
along with an incorporator material such as dextran (Feridex IV®), carboxydextran 
(Resovist®), chitosan[25], starch[26], lipid[27], among others. Superparamagnetic substances 
have mutually aligned magnetic ions, which allow them to have higher relaxivities compared 
to the ones of paramagnetic substances. 
  
Table 1.2 Non-exhaustive list of MRI approved contrast agents used in clinical practice 
(Adapted from [16], [28] and [29]) 
Contrast agent Composition Classification Target 
Feridex IV®  SPIO+dextran T2-agent Suspected liver metastases 
Resovist® SPIO+carboxydextran T2-agent Suspected liver metastases 
Gastromark® SPIO+silane T2-agent Bowel marker 
Magnevist® Gd+DTPA T1-agent Extracellular agent 
Omniscan® Gd+DTPA+BMA T1-agent Extracellular agent 
ProHance® Gd+DO3A+HP T1-agent Extracellular agent 
Dotarem® Gd+DOTA T1-agent Extracellular agent 
Gadovist® Gd+DO3A+Butriol T1-agent Extracellular agent 
Multihance® Gd+BOPTA T1-agent Liver specific agent 
Teslascan® Mn+DPDP T1-agent Liver specific agent 
MR contrast may also be enhanced by the presence in vivo of paramagnetic substances, 
commonly metal ions with unpaired electrons such as gadolinium (Gd3+), manganese (Mn2+, 
Mn3+), iron (Fe2+, Fe3+), copper (Cu2+)[30], cobalt (Co2+)[31] lanthanide ion series (La3+) and 
dysprosium (Dy3+)[32].  The first generation of such contrast agents consists on T1-agents, 
namely Gd complexes. Gadolinium has seven unpaired electrons and a large magnetic 
moment making it close to ideal to use as an MRI contrast agent. However, Gd and other 
metal ions cannot be used in the ionic form due to undesirable biodistribution and moderately 
high toxicity. For this reason, paramagnetic metal ions have been complexed with ligands to 
form chelates that are excreted intact from the body, reducing toxicity. The mentioned 
ligands include DTPA (Magnevist®), DOTA (Dotarem®) and other derivatives. 
Even though iron oxide nanoparticles seem the most promising in MRI contrast agent 
applications, there are still many challenges to overcome in the formulation of these 
structures. One of those is to develop a coating material capable of stabilizing the iron oxide 
particle and also provide controllable functional active groups to allow bioconjugation of 
specific ligands, which, for example, dextran is not capable of. Considering its in vivo use, 
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iron oxide particles of small size (5-150nm) and high mass magnetization are desired in 
addition to the proposed target specificity. 
 
1.2.2.1 - Hydroxyapatite-based nanoparticles as MRI contrast agents 
Hydroxyapatite Ca10(PO4)6(OH)2 is a bioceramic material with a calcium-to-phosphorus 
ratio similar to that of natural bone and teeth, being biocompatible, bioactive and 
biodegradable, therefore, with great clinical interest. It has been used for medical purposes 
over the last three decades, firstly in the form of implants for bone reconstruction [33-35]. 
HAp is also produced in form of powders, scaffolds and coatings over metallic implants or 
composites, which was referred to increase the osteoconductive properties of the implant, 
facilitating new bone formation and reducing recovery time after surgery[36, 37]. Nanosized 
HAp possessing uniform size and morphology has many applications in different fields of 
medicine and it its currently being tested as delivery vehicle of growth factors[38], 
antibiotics, anticancer drugs[18], enzymes, genes[39], among others. 
Also, some physicochemical properties of the apatite structure allow it to be dominated 
by different compositions, therefore, allowing an easy incorporation of ions in the crystal 
lattice. The calcium ions can be exchanged with most cations without affecting the stability 
of the phosphate [40]. All facts considered build the assumption that this biomaterial is a 
plausible candidate for its integration with a magnetically responsive nanoparticle in order to 
form a contrast agent compound.  
So far, several methods of preparing HAp nanoparticles have been exploited in the 
literature, namely sol-gel, biomimetic deposition, electrodeposition[41], ultrasonic spray 
freeze-drying, spray dry, combustion synthesis[42], being wet precipitation the easiest and 
more widely used technique. Briefly, this method can be translated into the following popular 
reaction scheme:  
Equation 1 is the reaction between calcium hydroxide and ortho-phosphoric acid is usually 
preferred because it has a simple formulation with the advantage of water being the only 
byproduct. However, hydroxyapatite precipitation is still a relatively complex process which 
depends on several parameters (calcium and phosphate ion concentration, pH, temperature, 
etc.) that influence final morphology, size and even chemical formulation[43]. 
Concerning the formulation of a MRI contrast agent consisting of HAp nanoparticle with 
incorporated magnetic substances, efforts have been made in this direction (Table 1.3).  
The workgroup of Feng-Huei Lin produced Fe2+ loaded Hap nanoparticles by the wet 
chemical precipitation method and tested them in vitro(2007)[44] and in vivo(2009)[45], for 
hyperthermia cancer therapy or image enhancer for MRI applications. These NPs were 
characterized by a size distribution between 20 and 50nm with aggregated sphere shape. 
Their individual morphology was categorized as short-rod and sphere. Concerning in vitro 
cytotoxicity results in a mouse embryonic fibroblast cell line (3T3), magnetic NPs were not 
harmful to the cultured cells. When injected subcutaneously in mice, the newly-formed NPs 
powders showed signs of biocompatibility, with bone metabolism not disturbed. However, 
their liver metabolism was affected, showing signs of hepatitis, but with no seriously 
damaged or fatal outcome. 
Petchsang et at.[46] presented some interesting results on studying magnetic properties 
of monodisperse Cobalt-ferrite-doped hydroxyapatite nanoparticles of approximately 90nm of 
5Ca(OH)2 + 3H3PO4  Ca10(PO4)6(OH)2 + 9H2O                                                             (1) 
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diameter, generated by a microwave irradiation technique. The team targets MRI contrast 
agent as a main focus for the synthesized particles, but also including other biomedical 
applications such as hyperthermia treatment of cancer or magnetically target drug delivery. 
The produced nanoparticles presented a clearly distinct core consisting of Co-ferrite and a 
shell constituted by HAp with a spheroidal-like shape, as pictured in Figure 1.3. Cytotoxicity 
was not assessed in this work. 
 
Table 1.3 A summary of hydroxyapatite-based magnetic nanoparticles non-
commercialized developed for in vivo clinical imaging.   
Doping 
species 
Production method Size (nm) Morphology Targeting Motif In vitro 
cytotoxicity  
Year Ref. 
Fe(II) Wet chemical 
precipitation 
20-50 Spherical/rod-
like   
--- Mouse 
embryonic 
fibroblast cell 
line – signs of 
biocompatibility 
2007 [44] 
Fe(III)+Co Microwave irradiation 
technique 
90 Spheroids --- --- 2009 [46] 
Gd+Eu Wet chemical 
precipitation 
30 Spheres  Folic acid + 
polyethyleneimine 
HUVECs/L929/KB 
cells – signs of 
biocompatibility 
2009 [17] 
Gd+Eu Microwave irradiation 
technique 
10-50 Rod-like --- MGC-803 – signs 
of 
biocompatibility 
2011 [47] 
Fe(II)+Fe(III) Neutralization method 50-80 Needle-like --- Saos-2 – signs of 
biocompatibility 
2012 [48] 
 
 
 
 
Figure 1.3 Transmission Electron Microscopy image of the HAp nanoparticles loaded with 
CoFe2O4, highlighting their core-shell structure. 
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On the other hand, Ashokan[17] tested the potential of multi-modal HAp nanoparticles 
doped with paramagnetic Gd and Europium and functionalized with folic acid (nHAp) and 
polyethyleneimine, in order to specifically target cancer cells and serve as a multi-modal 
contrast agent for three clinical imaging modalities (MRI, X-ray imaging and NIRF). These 
were produced by wet chemical precipitation method which originated nearly 80% of 
monodisperse non-functionalized particles with ~30nm diameter and spherical shape. In 
addition, the new particles showed better magnetic properties with brighter contrast than 
the clinically used Gd-DTPA (Magnevist®), in Figure 1.4. In vitro cytotoxicity studies using 
human umbilical vein endothelial cells and a cancer cell line revealed no apparent toxicity 
even up to relatively higher doses of 500 mg/mL.  
Feng Cheng et al. [47] also focused work on multifunctional Eu/Gd dual-doped 
hydroxyapatite nanorods for drug delivery applications with image guidance. Using a rapid 
microwave-assisted hydrothermal method, nanorods with diameter ranging between 10 and 
50nm were created. In addition, the synthesized NPs showed no appreciable toxicity in human 
gastric carcinoma cells.   
Silvia Panseri et al.[48] produced Fe(II)/Fe(III) doped HAP NPs by a neutralization method 
optimized by the group. Suggesting applications in bone tissue regeneration as well in 
diagnostic imaging or magnetic drug delivery, the proposed NPs with needle-like structure 
registered sizes of 5-20nm in width and up to 50-80nm in length. In vitro results showed that 
these NPs did not reduce osteoblast-like cell viability.  
As described above, magnetic nanoparticles can provide excellent performance as 
contrast agents and once injected in the blood stream they can be monitored by MRI. 
However, the distribution kinetics of current commercially available nano-contrast agents is 
described as passive or non-targeted, which restricts their clinical application.  Consequently, 
considerable efforts are focused on the preparation of targeted magnetic nanoparticles to 
expand the range of pathologies to which these contrast agents could be applied. In addition, 
Figure 1.4 Nuclear Magnetic Resonance images of doped nHAp in comparison to Gd-DTPA 
(Magnevist®) showing T1-weighted bright contrast.    
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magnetic NPs can be regarded as 3D platforms onto which different molecules can be 
assembled, such as drugs for cancer theranostics (imaging and diagnostics). 
 
1.3 - Next generation multifunctional nanoparticles for 
cancer imaging and therapy 
It is believed that the future of clinical oncology relies on the detection and treatment of 
malignant solid tumors in the earliest stage possible, increasing the chances to eradicate it. 
For this reason, it is highly anticipated that third generation magnetic nanoparticles can not 
only provide sensitive imaging information in cancer patients but also selectively deliver 
anticancer drugs to tumor sites. Besides early cancer diagnostic, this strategy would also be 
able to surpass the poor specificity and dose-limiting toxicities of pharmacologically active 
cancer drugs during current chemotherapy.  
Nevertheless, this goal faces many challenges, namely the delivery of the probe to the 
targeted tumor along with its biocompatibility and toxicity, the stability of the probe onto 
the nanoparticle and the effectiveness of the signal enhancement in vivo. 
Concerning tissue/organ-specific contrast agents, they usually consist of a coated 
paramagnetic or superparamagnetic label and a target-group molecule – probe – having a 
characteristic affinity for a specific cell or receptor. One of these probes believed to be 
highly specific against some cancers are monoclonal antibodies, such as an antibody against 
the endothelial integrin αvβ3 expressed on growing angiogenic vessels in some tumors (still not 
commercialized)[49]. Other target ligands involve soluble metalloporphyrins since they seem 
to have preferential selective uptake and retention by tumor tissues, folic acid once it binds 
to the high affinity folate receptors that exist in the serum of cancerous patients and on the 
cell surface of several human cancers of epithelial origin, bioactive peptides, sialic acids, 
among others[16].  
For tumor-targeted therapy, methods to increase the loading capacity of anticancer drugs 
in the nanoparticles and control their release at target cells remain quite challenging. 
 
1.4 - Aim and outline of the thesis 
Most cancers have the ability to invade and destroy adjacent structures, developing 
permissive niches that promote tumor cell survival and proliferation and possibly cause death. 
Not only cancer is a major public health problem registering an exponential increase in new 
cases every year, but it also constitutes a great economic impact worldwide. So, even though 
research efforts to improve current cancer therapies over the past three decades have led to 
an improvement in patient survival, there is still a need for new and better strategies. 
Early detection of cancer disease allows the maximum likelihood of successful treatment 
and recovery, since early localization of malignant solid tumors may allow a directed therapy 
to its site, optimizing the efficacy of the treatment. However, the most commonly used 
imaging modalities in clinical detection of cancer are all nonspecific, therefore they cannot 
distinguish between malignant or benign tumors and none leads to 100% accurate detection. 
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MRI is a non-invasive and commonly used imaging modality that can maximize its 
diagnostic value with the combined use of magnetic contrast agents. In addition, MRI contrast 
agents with nanometric dimensions constitute a very powerful tool in cancer therapy and 
diagnosis possessing distinct advantages over conventional ones due to some key 
characteristics such as their small size and high surface area, the possibility of delivery to a 
specific cancer site by active targeting and the possibility of engineering their blood 
circulation half-life, among other features. 
Although some nano-contrast agents have been proposed so far, cytotoxicity is still a 
major issue that endangers their clinical use. Hydroxyapatite is a bioceramic material that 
enables the inclusion of ions in its crystal lattice and also confers biocompatibility to the 
system which makes its conjugation with magnetically responsive ions an appealing approach 
in targeted cancer imaging.  
As previously described, some efforts to develop hydroxyapatite-based MRI contrast 
agents have been made. Nevertheless, there is a need to standardize the procedures of 
fabrication of the magnetic NPs. Also, it is not included in the literature a study that 
compares different doping agents produced by the same method and tested on the same 
parameters.   
This project main goal is to produce, characterize and compare hydroxyapatite 
nanoparticles doped with particular magnetic species (Gd, Fe(II), Fe(III) and Co) and 
ultimately infer about their potential as MRI contrast agents. This main goal can be divided 
into smaller tasks that consist on: 
 Choose the right method a optimizing the available conditions in order to produce 
doped nanoparticles with sizes between 10 and 100nm; 
 Characterize the produced NPs in terms of their size, magnetic properties and 
also characterize the process of ion doping and its influence on the HAP structure; 
 Evaluate any toxic effects of the doped NPs in a common cell line in a certain 
time frame.   
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  Chapter 2
Materials and Methods 
2.1 - Synthesis of the Hydroxyapatite-based nanoparticles 
The hydroxyapatite-based nanoparticles were prepared by the wet chemical precipitation 
method. In a typical synthesis procedure of pure hydroxyapatite nanoparticles, 40mL of 0.5M 
Ca(OH)2 (98% extra pure, Acros Organics) was prepared and heated to 100ºC to which 40mL of 
0.3M H3PO4 (85 wt% solution in water, Acros Organics) was added at a rate of 500µL/min. At 
this point, the magnetic dopants Gadolinium chloride hexahydrate Cl3Gd.6H2O (99%, Sigma 
Aldrich), Cobalt nitrate hexahydrate Co(NO3)2.6H2O (98+%, Acros Organics), Iron nitrate 
nonahydrate Fe(NO3)3 9H2O (98+%, Acros Organics) and Iron chloride tetrahydrate FeCl2.4H2O 
(99+%, Acros Organics) were added simultaneously with the phosphate precursor H3PO4 
dropwise to the Ca(OH)2 solution at the rate of 500µL/min to produce doped hydroxyapatite 
nanoparticles. The amount of dopant ions added depended on the required percentage of 
doping (2.5%, 5% and 10%) with respect to the atomic percentage of Ca2+. The applied 
nomenclature to the nanoparticles is formatted as XY_HAP, where X is the doped magnetic 
ion and Y represents the percentage of doping. All solutions were prepared with deionized 
water and the (Ca+doping ion)/P molar ratio was maintained at 1.67 in all procedures. 
The reaction was carried out at 100ºC in a water bath with constant stirring of 650rpm, as 
portrayed in figure 2.1. Throughout the reaction, pH was maintained at ~7.4 using ammonium 
hydroxide (25% solution in water, Acros Organics). After the reaction, the mixture was kept in 
these conditions for 2 hours and then incubated at room temperature overnight. Prior to the 
drying step at 60ºC, samples were centrifuged (5 min, ~2070g) and washed 3 times with hot 
deionized water. Finally, all nanoparticles were powdered using mortar and pestle and stored 
in a desiccator for further use. This protocol was adapted from the one described by Ashokan 
et al [17].   
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2.2 - Physicochemical Characterization 
2.2.1 - Size, morphology and zeta potential 
Transmission electron microscope (TEM) was employed for high resolution imaging of pure 
and doped nanoHAP. A Jeol JEM 1400 microscope was used to observe nanoparticle size and 
morphology. To prepare samples for observation, the powders were suspended in deionized 
water using a concentration of 0.05g/L and the dispersant sodium dodecyl sulfate (SDS, 20% 
solution in water, Sigma Aldrich) was added in a concentration of 10x10-3 mol/L. Solutions 
were then sonicated for 15 seconds (20x) (Sonics&Materials, VC50) and applied to a copper 
grid. Images were examined using ImageJ® software to quantify nanoparticles dimensions.    
The zeta potential and size of the synthesized nanoparticles were measured with a 
ZetaSizer Nano ZS. This device uses Dynamic Light Scattering (DLS) and calculates the particle 
size distribution from their diffusion under Brownian motion and applying the Stokes-Einstein 
relationship, D=kT/3πηDH, where D is the translational diffusion coefficient of a spherical 
particle in a fluid, k is the Boltzmann’s constant, T is the absolute temperature, η is the 
viscosity and DH is the hydrodynamic diameter.       
On the other hand, zeta potential is calculated through the particles electrophoretic 
mobility which is the movement of a charged particle relative to the liquid when an electric 
field is applied. A laser beam hits the moving particles and induces a change of frequency by 
the Doppler Effect. This difference is proportional to the electrophoretic mobility (UE) and 
zeta potential (z) is analyzed according to Henry’s equation, UE=2εzf(Ka)/3η, where ε is the 
dielectric constant, f(Ka) is Henry’s function and η is the viscosity[50].     
For this characterization, the powders were suspended in deionized water and prepared 
the same way as for TEM observations. 
Figure 2.1 Representation of the nanoparticles fabrication conditions. a-Peristaltic pump; b-
temperature controller and heating plate with magnetic stirrer; c-pH meter.  
a. b. c. 
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2.2.2 - Chemical profile 
The infrared spectra that contain the species characteristic chemical bonds were 
recorded with a Fourrier Transform Infrared (FTIR) spectrometer Perkin-Elmer 2000 with a 
4cm-1 spectral resolution and 100 scans per sample. In order to perform the analysis, ~2mg of 
each powdered sample was mixed with ~200mg of potassium bromide KBr to maintain low 
levels of humidity and discs were produced in a uniaxial press (Grasedy Specac). 
2.2.3 - Crystal phase analysis 
In order to infer about the particles crystallinity before and after doping, X-ray diffraction 
(XRD) measurements were made. For this technique, samples were sintered to improve the 
obtained signal. The nanoHAP powders were heated up to 1000ºC at a rate of 4ºC/min and 
then heat-treated for 1h at this temperature, being the appropriate sintering temperature for 
nanosized HAP prepared by this method[41].  
The x-ray diffraction patterns were obtained in a PANalytical X’Pert PRO TCU 1000 
diffractometer, using monochromatic Cu radiation (λ = 1.541874Å). Data were acquired for 2Θ 
values between 8º and 100º with steps of 0,008º. Commercialized undoped nanoHAP was 
analyzed by other team member and was used as a control after heat-treatment.   
2.2.4 - Magnetic properties 
The magnetic properties of the doped and undoped nanoparticles were studied by 
superconducting quantum interference device (SQUID, Quantum design Ref: MPMS-5S) in an 
applied magnetic field of•±50 kOe at 300K. The strength of the magnetic moment is 
presented as a mass magnetization (M) – magnetic moment per total mass of each sample. 
For these measurements, the previously prepared powders were weighed and inserted in a 
see-through capsule and, in turn, the capsule was inserted in a see-through straw that is 
introduced into the SQUID magnetometer for further analysis.  
   
2.3 - Biological response 
2.3.1 - Cell culture and maintenance 
Human Dermal Microvascular Endothelial Cells (hDMECs) were purchased from ScienCell 
Research Laboratories (Catalog number: 2000) and cultured in Endothelial Cell Basal medium 
(EBM®-2, Clonetics Lonza) supplemented with 2% foetal bovine serum (FBS), 0.04% 
hydrocortisone, 0.4% human recombinant fibroblast growth factor-β (rhFGF-β), 0.1% vascular 
endothelial growth factor (VEGF), 0.1% ascorbic acid, 0.1% Gentamicin Sulfate and 
Amphotericin-B, 0.1% heparin, 0.1% human recombinant epidermal growth factor (rhEGF) and 
0.1% recombinant long R insulin-like growth factor-1 (R3-IGF-1) . The medium was renewed 
every 2-3 days until confluence was reached and cells were used until passage 7. All the 
procedures described with live cells were performed in sterile conditions on a laminar flow 
chamber and incubation was carried out in a 5% CO2 and 37 °C atmosphere.  
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2.3.2 - Cell metabolic activity evaluation  
In order to estimate the in vitro cell viability of the nanoHAP with the highest doping 
concentration (10%) of Gd, Fe(II), Fe(III) and Co, a resazurin (Sigma) assay was performed. 
This method is based on a cell viability indicator that uses natural reducing power of living 
cells to convert resazurin to the fluorescent product, resofurin. Fluorescence acts as a 
proportional response of cell metabolic activity[51].  
Each well of the 96-well plate was seeded with 5000 hDME cells. After 24h of culture, the 
medium in the wells was refreshed with the medium containing autoclaved nanoparticles at a 
concentration of 500µg/mL. Finally, cells were incubated with new medium and resazurin 
assay was performed at the time points of 4h and 24h. Briefly, after previously removing the 
culture medium form the wells, resazurin was added in fresh medium at a final concentration 
of 10% (v/v) and incubated for 4h, at 37ºC. 100μL of medium was then extracted from each 
sample and fluorescence was measured at λex=540nm and λem=590nm in a microplate reader.  
2.3.3 - Cellular morphology 
After 4 and 24 hours of culture, cell morphology was observed by staining the F-actin with 
Alexa Fluor ® 488 phalloidin (Invitrogen, Molecular Probes) and counterstaining the nuclei 
with DAPI (4',6-diamidino-2-phenylindole, Merck). Culture medium was removed from the 
wells and samples were washed 2x with PBS and fixated with 4% formaldehyde at room 
temperature (RT) for 15 minutes. After washing with PBS twice, cells were permeabilized for 
30 minutes with 0.1% (v/v) Triton X-100 and washed again 3x with PBS. The samples were 
then incubated with the phalloidin diluted 1:100 in PBS for 30 minutes in the dark at RT and 
washed 3x with PBS. To stain the nuclei of the cells, samples were incubated with DAPI at a 
concentration of 0.1µg/mL in PBS for 10 min and washed with PBS 3x. Two drops of 
FluoromountTM were added and the samples were stored at 4ºC in the dark until observation 
under an inverted fluorescence microscope with proper light filters.  
2.3.4 - Statistical analysis 
Data from the resazurin assay were analyzed using Scheffe test for multiple comparisons. 
Results were considered significant when p<0.05. Calculations and descriptive statistic were 
performed using SPSS-Software for Windows® (version 17.0) and Microsoft Office Excel 2010®. 
All data are presented as average values ± standard deviation. 
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  Chapter 3
 
Results and Discussion 
3.1 - Physicochemical Characterization 
3.1.1 - Size, morphology and zeta potential 
Both size and morphology of nanoparticles synthesized as MRI contrast agents influence 
their interaction not only with each other in a suspension, but also with the cells they are in 
contact with.  
 
Undoped HAP 
 
Gd10_HAP Gd5_HAP Gd2.5_HAP 
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Fe(II)10_HAP Fe(II)5_HAP Fe(II)2.5_HAP 
Fe(III)10_HAP Fe(III)5_HAP Fe(III)2.5_HAP 
Co10_HAP Co5_HAP Co2.5_HAP 
Figure 3.2 TEM images of the undoped and doped nanoHAP 
Figure 3.1 NanoHAP dimensions obtained with TEM images (Figure 3.1) observation through Image 
J® software 
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The TEM image (Figure 3.1) of undoped hydroxyapatite indicates the formation of 
spherical nanoHAP of average size ~11 nm. On the other hand, all images of doped 
nanoparticles show a predominant more elongated shape that can be identified as a rod-like 
shape. In addition, these species present slightly higher dimensions, as also shown in Figure 
3.2. The studied doped nanoparticles present longitudinal dimensions between ~34 and 
~59nm and cross sectional dimensions between ~15 and ~29nm. These differences in size and 
morphology from the doped and undoped species might have been induced by differences in 
electric charge and ionic radius between the Ca2+ ions and the Gd3+/Fe2+/Fe3+/Co2+ doping 
ions. This may be influencing the crystal growth of nanoHAp, leading to altered size and 
shape of doped NPs compared to undoped NPs, as suggested by other authors in similar 
studies[47].  
 Considering the main application of the synthesized nanoparticles in tumor cells imaging 
and future applications in tumor cell specific targeting, ligand coated NPs can be efficiently 
directed toward and subsequently internalized by tumor cells. However, cellular uptake of 
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Figure 3.3 ZetaSizer results displaying (A) the average particle sizes and (B) the average zeta 
potential of the doped and undoped nanoHAP 
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NPs is size-dependent and some authors have found 40-60nm to be the optimal NP size range 
for endocytosis and mediation of other signaling processes [52, 53]. Consequently, the results 
obtained through TEM observation are in agreement with those described in the literature. 
In relation to the shape of the particles, although there is a lot of unconformity among 
authors, recent findings indicate that rod-like shaped nanoparticles are significantly better in 
cancer targeting, exhibiting higher specific uptake and lower nonspecific uptake in breast 
cancer cells compared with spherical nanoparticles [54]. This also constitutes a positive 
indicator that the doped nanoHAP produced in this work is suitable for targeted cancer 
imaging.     
Comparing the TEM results to the ones obtained with the ZetaSizer, size measurements 
differ. As portrayed in Figure 3.3A, the studied doped and undoped nanoparticles present 
sizes between a range of 155 and 244nm. Size between both methods differs due to the fact 
that ZetaSizer uses DLS technology whose approach recognizes each particle as a perfect 
sphere that does not represent the actual shape of the synthesized NPs. Also, the ZetaSizer 
measurements most likely represent the size of NPs aggregates that were not effectively 
dispersed after sonication.   
Concerning the measured zeta potential of the samples, it fluctuates between -45 and -
34mV with small deviations (Figure 3.3B). All preparations consisted on stable colloidal 
suspensions either at or above critical micelle concentration for the negatively charged 
surfactant SDS which explains the strongly negative zeta potential obtained in all 
suspensions[55].  
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3.1.2 - Chemical profile 
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In order to chemically characterize the process of ion doping in terms of changes in the 
nanoHAP profile, a FTIR analysis was performed (Figure 3.4). 
Considering all the represented species, the FTIR spectra are characterized by lattice 
(~3573cm-1) and vibrational (~634cm-1) OH bands, phosphate bands (ʋ1~962cm-1, ʋ2 ~470cm-1, 
ʋ3 ~1090-~1110 and ~1035cm-1, ʋ4 ~603 and ~565cm-1), residual carbonates C-O resulting from 
the atmospheric CO2 adsorbed by the apatite (~1457, ~1421 and ʋ2 ~876cm
-1) and lattice 
water (3417-3495cm-1 and ~1637cm-1) which are typical in a nanoHAP spectra [17, 44, 56-58]. 
All species also present a few weak peaks 2500-2000cm-1 that might correspond to HPO4
2- 
groups as previously reported in the literature[59].   
In a more close analysis to each type of ion doping into nanoHAP, the addition of Gd 
increases the intensity of the band assigned to moisture in the samples (2500-3500cm-1)[60] 
and also increases the intensity of the peak assigned to the hydroxyl groups (3570 cm-1) but 
does not significantly affect the rest of the spectra(Figure 3.4A). Fe(II) doping also produces a 
similar effect to the referred water band and hydroxyl peak (Figure 3.4B) and Fe(III) shows 
only a major increase in intensity of the hydroxyl peak, compared to pure HAP(Figure 3.4C). 
Cobalt insertion in the HAP matrix does not significantly alter the spectra compared to the 
nanoHAP one. A sharp peak is also found in Co10_HAP ~800cm-1 which might correspond to 
the presence of some remaining nitrate from the used reagents [61, 62].   
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3.1.3 - Crystal phase analysis  
 
 
XRD technique was used to infer about phase composition and crystallinity of the HAP 
nanoparticles after magnetic ion doping. Figure 3.5 shows the XRD patterns of some heat-
treated samples that were successfully analyzed and compared to commercialized undoped 
nanoHAP.  
In Gd5_HAP and Co5_HAP, no unexpected phase was formed and all peaks correspond 
solely to hydroxyapatite phase, accordingly to Centre for Diffraction Data (ICDD) standard 
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Figure 3.5 X-ray diffraction pattern of commercialized pure HAP, Gd5_HAP, Co5_HAP and 
Fe(II)HAP. Blue symbols indicate the presence of whitlockite peaks on Fe(II)10_HAP among the 
hydroxyapatite composition  
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data (PDF file #9-432). However, XRD analysis of Fe(II)10_HAP indicated the presence of 
whitlockite, a form of calcium phosphate, between the hydroxyapatite composition. This 
could have formed during heat-treatment and propitiated by the Fe(II) content of the sample, 
which might be modifying the apatite structure and producing secondary phases[63].  Further 
sample analysis is needed.     
 
3.1.4 - Magnetic properties 
According to the main objective of this work towards developing a robust and 
reproducible contrast agent system capable of enhancing tumor contrast, it was important to 
illustrate the magnetism of the synthesized doped nanoHAP. The relationship of 
magnetization to applied field (±50kOe) at room temperature of the nanoHAP with different 
doping ions is plotted in figure 3.6.   
In all doped nanoparticles (Gd_HAP, Fe(II)_HAP, Fe(III)HAP and Co_HAP), the 
magnetization level increased with the doping concentration of each ion, confirming their 
predominant role in making these nanoparticles magnetically functional.  
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Figure 3.6 Variation of magnetization with the applied field of ±50kOe for synthesized doped and 
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These results were also found in previous similar studies [17, 44, 47], where also the 
magnetization level of doped NPs exhibit an increase with the ion doping concentration. In 
addition, it was not observed a magnetization unexpected shift in any sample, which could 
have happened in a case where the ion doping percentage is excessive to the point where it 
affects the arrangement of the crystal structure of the particles, reducing their magnetic 
moment.      
When comparing the nanoparticles of the highest doping percentage with the undoped 
nanoHAP (Figure 3.6E), it is clear that pure hydroxyapatite remains diamagnetic. Also, it can 
be noted that the maximum magnetic moment of the NPs varies with the correspondent 
doping ion, having Gd10_HAP the highest and Co10_HAP the lowest. This is also expectable 
due to their intrinsic electronic configuration[64].  
In order to have a positive control over the produced NPs, a Gd-based commercially 
available MRI contrast agent Dotarem® was also measured, since it is one of the currently 
most used contrast agents for MRI exams. It is clear and expected that Gd10_HAP shows the 
most similar behavior compared to Dotarem®. In addition, Gd10_HAP has also the closest 
magnetic moment to the Dotarem® one which makes it very appealing as a hydroxyapatite-
based MRI contrast agent since this characteristic allows the NPs to exhibit the highest 
relaxivity values[64]. 
Since the drive of this study is to produce a base nano-contrast that could increase the 
sensitivity of MRI to detect molecular targets, the fact that Gd_HAP presents the best 
magnetic properties is important. As a paramagnetic T1-agent, it provides a bright signal that 
is not easily mistaken for other pathogenic or biological conditions which maximizes the 
potential of MRI anatomical imaging.     
3.2 - Nanotoxicity analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Cell metabolic activity assay (resazurin) of hDMECs cultured for 4 and 24h with doped 
and undoped nanoHAP at a concentration of 500µg/mL. * indicates a significant statistical difference 
between TCPS 24h and all the other groups (p<0.05; n=5)  
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Cell viability of many recently developed nano-sized contrast agents is a major issue that 
endangers their clinical use. In this regard, the aim of this study was to verify toxic effects 
induced by the doped NPs compared to the undoped HAP and for this purpose, two parallel 
assays were performed analyzing hDMECs metabolic activity (Figure 3.7) and respective 
morphology (Figure 3.8). As previously stated, highest ion doping corresponds to a higher 
magnetic moment and, consequently, a higher potential as an MRI contrast agent. Therefore, 
the NPs with the highest value of ion doping were further investigated in this assay to assess 
on their biocompatibility. 
After 4h of culture, there are no statistically relevant differences between the cells 
metabolic activity in the different tested conditions. However, after 24h of incubation, 
hDMECs cultured in TCPS have a statistically significant higher metabolic activity compared to 
the other conditions. These results seem to indicate that none of the synthesized NPs is 
particularly toxic for this primary cell line in the studied time frame. This is an important 
finding because in clinical medical applications primary endothelial cells are one of the firsts 
to be in contact with the NPs. It should be noted that the nanoparticles concentration used 
for the cellular studies (500µg/mL) is one of the highest concentrations tested by other 
authors in similar studies [17, 44], making the present results a more positive indicator of the 
NPs biocompatibility in this cell line. Moreover, although this concentration is much lower 
than the one used in vivo for commercially available contrast agents (279,32mg/mL in 
Dotarem® and recommended 0,2mL/kg for intravenous administration), this consists of an in 
vitro adaptation with much less cellular mass involved.  
 Attending on the time frame chosen for this preliminary assay, it was taken in account 
that, for example, Dotarem® has an average blood circulation half-life of 30 min[17] and 
approximately 80% of the compound is excreted within 48h after injection[65], therefore the 
initial 24h response to the contrast is the most relevant in terms of cytotoxicity effects. 
Furthermore, this is also a parameter that could be optimized in the synthesized NPs with 
proper functionalization, since their blood circulation time could be prolonged in comparison 
to Dotarem®. Optimizing this characteristic would be useful, for example, in cancer imaging 
and treatment using the EPR effect described previously. Briefly, due to the anatomy of 
tumor vasculature, nanosized particles can migrate from the blood pool to the tumor tissues 
and can be retained due to poor lymphatic drainage, but for this approach to be effective the 
blood half-life of the particles should be at least of 6h [66].   
In order to reinforce the previously obtained results, hDMECs were stained in parallel with 
the cell metabolic activity assay to search for abnormalities in cells morphology and 
proliferation. 
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Figure 3.8 Morphology observation of hDMECs cultured for 4 and 24h with doped and undoped 
nanoHAP. Double nuclei characteristic is highlighted in picture A (Fe(II)10_HAP after 4h of culture). F-
Actin is shown in green and cells nuclei in blue. Magnification 10x. 
The results found seem to be in accordance to the ones extracted from the cell metabolic 
activity assay. 
Interestingly, it is possible to observe in each substrate what resembles cells going 
through the mitosis process with double nuclei in the same cytoplasmic area (highlighted by 
white arrows in Figure 3.8 and by white square in Figure 3.8A). Another interesting 
characteristic is the heterogenic morphology of hDMECs in both time points, existing clear 
differences in the size of the cells which also suggests that these cells are proliferating at 
different stadiums. Nonetheless, there does not seem to be a morphological change between 
time points in all conditions which might suggest that these NPs are biocompatible for this 
cell type in the studied time frame.  
However, the toxic effect of NPs in cells is not necessarily connected with the death of 
cell populations. They can also be associated with deviations in the fate of the cells, for 
instance alter their capacity to differentiate, as shown by Pisanic et al.[67].  For this reason, 
further tests should be addressed in order to fully comprehend the synthesized NPs effect in 
the cultured hDMECs. One important parameter is the oxidative stress caused within the cells 
that could lead to adverse biological effects[68], therefore the intracellular reactive oxygen 
species released in cells incubated with the NPs could be further investigated.   
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  Chapter 4
 
Conclusions and future perspectives 
In this study, both hydroxyapatite and magnetic ion doped hydroxyapatite nanoparticles 
were successfully produced by a well-controlled wet chemical precipitation method.  
The obtained magnetically doped particles have a rod-like shape with sizes that vary 
approximately between 30 and 60nm that do not fluctuate with doping percentage. These 
characteristics are considered optimal for cell endocytosis and cancer targeting. 
 It was shown that the doping concentration with respect to the atomic percentage of Ca2+ 
does not significantly alter the HAP structure although it has a predominant role in the 
magnetic properties of the nanoparticles. 10% Gd doped HAP presented the highest magnetic 
moment levels compared to the Fe(II), Fe(III) and Co ones and the closest values to 
Dotarem®.   
Viability and morphology of human dermal microvascular endothelial cells did not seem to 
be significantly altered after incubation with the synthesized materials. 
The results achieved in the present project suggest that from the produced and tested 
magnetically responsive nanoparticles, Gd10_HAP seems to detain the highest potential for 
medical applications in the future as a versatile and customizable paramagnetic T1 MRI 
contrast agent.  
 
Future perspectives 
 
To increase the knowledge about the synthesized nanoparticles, XRD analysis should be 
further completed along with the Rietvelt method in order to fully understand the aspects in 
which the ion doping alters the nanohydroxyapatite core structure. 
In order to quantify the effective concentration of doping agent in each sample, an 
Inductively Coupled Plasma (ICP) could be performed.  
A curious complement could be the obtainment of MR images of the samples to compare 
the contrast provided by all the doped nanoparticles, also in comparison to Dotarem®.  
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Next step would also be to continue the in vitro work, repeating the cell viability studies 
possibly prolonging them and performing a cellular biodistribution assay to infer about the 
cellular uptake and stability of the nano-contrast. Haematocompatibility studies should also 
be annexed to this work, keeping in mind the in vivo application of these agents in the blood 
stream.  
An interesting and following phase would be to create a cell tumor model and optimize a 
suitable cancer target ligand to explore the targeted cancer imaging promising approach. 
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